At Quantiscope®, every picture is worth a thousand data points. Our PhenotypIQ® enterprise platform leverages AI to transform microscopic images into quantifiable, actionable phenotypic data, enabling a global community of researchers and regulators to develop better, faster, and safer therapies for people and planet.
PhenotypIQ = Automation of Biological Quantification
What we do
Currently, phenotypic modeling is conducted via a hodgepodge of open source and commercial tools, trained on outdated and unreliable data sets, and lacking new advances in imaging and NLP AI.
We are incorporating the latest advances into plug-and-play, team-oriented dashboards to enhance drug discovery decision making throughout organizations tasked with delivering the world’s critical biologic, chemical, and genetic therapies.
How it works
Machine Learning Field Segmentation
Our platform is designed for universal analysis of cells and subcellular structures without the need for labeling or conditional information of treatments or environmental constraints. Examining brightfield or stained high content images presented through our dashboard, PhenotypIQ accurately identifies cells and subcellular targets separated from background noise.
AI Cellular Feature Extraction
Our AI technology further selects from hundreds to thousands of nodes within the cellular or subcellular analysis target to develop relevant phenotypic signatures of variation for each cell or subcellular structure within a biological experiment or screen.
Aggregation of Individualized Morphological Signatures
Millions of signatures may be rapidly produced and aggregated through our cloud-based gpu architecture, with the signatures created based on potential for predictive ranking of candidate success or product viability. Aggregates of phenotypic signatures present as hierarchical rankings indicating e.g., which potential therapeutic candidates rank best and safest among a class, which batches of bio-manufactured product are viable in a distribution network, or which marketed oncology treatments are most suitable for an individual patient.
Kevin Christopher, JD/MBA
Co-Founder, CEO
Juan Caicedo, PhD
Co-Founder, CIO
Andrew Gabros
Co-Founder, CDO
Impact
Quantiscope PBC is a public benefit corporation launched from the Broad Institute of Harvard/MIT, and housed at Altitude Lab in Salt Lake City. Our PBC commitments include prioritizing diversity in leadership and use of our technology for the greatest global good.
We address U.N. SDGs 3, 10, 12, 13, and 17 by reducing use of biochemical resources in drug development, limiting dependency on animal models, increasing biotech innovation capabilities across distributed teams and in developing countries, speeding and de-risking development of therapeutics, increasing safety of bio-manufactured products along supply chains, and enabling novel agricultural solutions to enhance climate resiliency.
Contact
We’re looking for beta testers of our PhenotypIQ drug discovery platform, and innovation partners for drug safety, climate resilience, and personalized medicine.
Contact us at [email protected].
